Incidence and real-world burden of brain metastases from solid tumors and hematologic malignancies in Ontario: a population-based study.
brain imaging
brain metastases
incidence
intracranial metastatic disease
Journal
Neuro-oncology advances
ISSN: 2632-2498
Titre abrégé: Neurooncol Adv
Pays: England
ID NLM: 101755003
Informations de publication
Date de publication:
Historique:
entrez:
15
2
2021
pubmed:
16
2
2021
medline:
16
2
2021
Statut:
epublish
Résumé
Although intracranial metastatic disease (IMD) is a frequent complication of cancer, most cancer registries do not capture these cases. Consequently, a data-gap exists, which thwarts system-level quality improvement efforts. The purpose of this investigation was to determine the real-world burden of IMD. Patients diagnosed with a non-CNS cancer between 2010 and 2018 were identified from the Ontario Cancer Registry. IMD was identified by scanning hospital administrative databases for cranial irradiation or coding for a secondary brain malignancy (ICD-10 code C793). 25,478 of 601,678 (4.2%) patients with a diagnosis of primary cancer were found to have IMD. The median time from primary cancer diagnosis to IMD was 5.2 (0.7, 15.4) months and varied across disease sites, for example, 2.1 months for lung, 7.3 months for kidney, and 22.8 months for breast. Median survival following diagnosis with IMD was 3.7 months. Lung cancer accounted for 60% of all brain metastases, followed by breast cancer (11%) and melanoma (6%). More advanced stage at diagnosis and younger age were associated with a higher likelihood of developing IMD ( IMD represents a significant burden in patients with systemic cancers and is a significant cause of cancer mortality. Our findings support measures to actively capture incidents of brain metastasis in cancer registries.
Sections du résumé
BACKGROUND
BACKGROUND
Although intracranial metastatic disease (IMD) is a frequent complication of cancer, most cancer registries do not capture these cases. Consequently, a data-gap exists, which thwarts system-level quality improvement efforts. The purpose of this investigation was to determine the real-world burden of IMD.
METHODS
METHODS
Patients diagnosed with a non-CNS cancer between 2010 and 2018 were identified from the Ontario Cancer Registry. IMD was identified by scanning hospital administrative databases for cranial irradiation or coding for a secondary brain malignancy (ICD-10 code C793).
RESULTS
RESULTS
25,478 of 601,678 (4.2%) patients with a diagnosis of primary cancer were found to have IMD. The median time from primary cancer diagnosis to IMD was 5.2 (0.7, 15.4) months and varied across disease sites, for example, 2.1 months for lung, 7.3 months for kidney, and 22.8 months for breast. Median survival following diagnosis with IMD was 3.7 months. Lung cancer accounted for 60% of all brain metastases, followed by breast cancer (11%) and melanoma (6%). More advanced stage at diagnosis and younger age were associated with a higher likelihood of developing IMD (
CONCLUSION
CONCLUSIONS
IMD represents a significant burden in patients with systemic cancers and is a significant cause of cancer mortality. Our findings support measures to actively capture incidents of brain metastasis in cancer registries.
Identifiants
pubmed: 33585818
doi: 10.1093/noajnl/vdaa178
pii: vdaa178
pmc: PMC7872008
doi:
Types de publication
Journal Article
Langues
eng
Pagination
vdaa178Informations de copyright
© The Author(s) 2020. Published by Oxford University Press, the Society for Neuro-Oncology and the European Association of Neuro-Oncology.
Références
J Digit Imaging. 2019 Dec;32(6):1044-1051
pubmed: 31289979
J Med Imaging Radiat Oncol. 2018 Jun;62(3):383-388
pubmed: 29745036
Surg Neurol Int. 2013 May 02;4(Suppl 4):S245-55
pubmed: 23717796
Nat Rev Cancer. 2003 Jun;3(6):453-8
pubmed: 12778135
BMC Ear Nose Throat Disord. 2018 Aug 9;18:13
pubmed: 30116158
Curr Oncol Rep. 2012 Feb;14(1):48-54
pubmed: 22012633
JAMA Netw Open. 2020 Jul 1;3(7):e208204
pubmed: 32663310
Neurosurg Clin N Am. 2011 Jan;22(1):1-6, v
pubmed: 21109143
J Neurooncol. 2016 Sep;129(3):545-555
pubmed: 27456950
J Clin Oncol. 2004 Jul 15;22(14):2865-72
pubmed: 15254054
J Cancer Res Clin Oncol. 2018 Sep;144(9):1803-1816
pubmed: 29971531
Transl Lung Cancer Res. 2020 Jun;9(3):682-692
pubmed: 32676330
J Thorac Dis. 2018 Jul;10(Suppl 18):S2168-S2171
pubmed: 30123551
Neuro Oncol. 2017 Oct 19;19(11):1511-1521
pubmed: 28444227
Continuum (Minneap Minn). 2012 Apr;18(2):295-311
pubmed: 22810128
NPJ Precis Oncol. 2018 Feb 16;2(1):4
pubmed: 29872722
CA Cancer J Clin. 2016 Jul;66(4):271-89
pubmed: 27253694
BMC Ear Nose Throat Disord. 2018 Mar 21;18:4
pubmed: 29581706
Radiat Oncol. 2020 May 28;15(1):128
pubmed: 32466775
Int J Clin Oncol. 2018 Aug;23(4):641-646
pubmed: 29484515
J Neurooncol. 2005 Oct;75(1):5-14
pubmed: 16215811
Clin Breast Cancer. 2020 Feb;20(1):e54-e64
pubmed: 31447286
JAMA Oncol. 2017 Aug 1;3(8):1069-1077
pubmed: 28301662
JAMA Oncol. 2018 Jul 1;4(7):1001-1003
pubmed: 29799956
Cancer. 2003 Jul 15;98(2):363-8
pubmed: 12872358
Neuro Oncol. 2012 Sep;14(9):1171-7
pubmed: 22898372
Cancer. 2016 Jun 15;122(12):1921-7
pubmed: 27062154
Chest. 2016 Apr;149(4):943-50
pubmed: 26356134
Anticancer Res. 2012 Nov;32(11):4655-62
pubmed: 23155227